ERBB2 and neoplasm: Unlike many anti-HER2 therapies that require HER2 overexpression for efficacy, T-DXd remains effective in HER2-low tumors because of its membrane-permeable and highly potent payload, high drug-to-antibody ratio (8:1), and bystander effect on neighboring tumor cells.(13)